Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Stocchi

Showing results (141-150 of 254) with videos related to

Pageof 26
Sort By:
Journal of Parkinson'S Disease|September 6, 2021
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsRobert A Hauser, Nobutaka Hattori, Hubert Fernandez, et al.
Redox Biology|February 4, 2026
Are glutathionylated aldehyde reductases the missing piece of the "catecholaldehyde hypothesis" in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL)Rossella Rotondo, Marta Russo, Federico Iacovelli, et al.
Journal of Parkinson'S Disease|November 9, 2020
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized StudyC Warren Olanow, Alberto J Espay, Fabrizio Stocchi, et al.
Frontiers in Neurology|September 9, 2022
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A <i>post-hoc</i> analysis of BIPARK-I and IIJosé-Francisco Rocha, Georg Ebersbach, Andrew Lees, et al.
Frontiers in Neurology|November 22, 2021
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A <i>Post-hoc</i> Analysis of BIPARK-I and -IIJosé-Francisco Rocha, Georg Ebersbach, Andrew Lees, et al.
Plos One|March 8, 2013
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet needKallol Ray Chaudhuri, Jose Manuel Rojo, Anthony H V Schapira, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 3, 2024
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical StudyC Warren Olanow, Deborah McIntyre, Michele Matarazzo, et al.
Frontiers in Neurology|December 31, 2025
Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuationsJoaquim J Ferreira, Fabrizio Stocchi, Angelo Antonini, et al.
Neurology|June 15, 2014
Prevalence of fatigue in Parkinson disease and its clinical correlatesFabrizio Stocchi, Giovanni Abbruzzese, Roberto Ceravolo, et al.
Parkinson'S Disease|December 23, 2011
The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation projectVinod Metta, Kartik Logishetty, P Martinez-Martin, et al.
Pageof 26

Showing results (141-150 of 254) with videos related to

Sort By:
Pageof 26
Journal of Parkinson'S Disease|September 6, 2021
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 TrialsRobert A Hauser, Nobutaka Hattori, Hubert Fernandez, et al.
Redox Biology|February 4, 2026
Are glutathionylated aldehyde reductases the missing piece of the "catecholaldehyde hypothesis" in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL)Rossella Rotondo, Marta Russo, Federico Iacovelli, et al.
Journal of Parkinson'S Disease|November 9, 2020
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized StudyC Warren Olanow, Alberto J Espay, Fabrizio Stocchi, et al.
Frontiers in Neurology|September 9, 2022
The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A <i>post-hoc</i> analysis of BIPARK-I and IIJosé-Francisco Rocha, Georg Ebersbach, Andrew Lees, et al.
Frontiers in Neurology|November 22, 2021
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A <i>Post-hoc</i> Analysis of BIPARK-I and -IIJosé-Francisco Rocha, Georg Ebersbach, Andrew Lees, et al.
Plos One|March 8, 2013
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet needKallol Ray Chaudhuri, Jose Manuel Rojo, Anthony H V Schapira, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 3, 2024
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical StudyC Warren Olanow, Deborah McIntyre, Michele Matarazzo, et al.
Frontiers in Neurology|December 31, 2025
Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuationsJoaquim J Ferreira, Fabrizio Stocchi, Angelo Antonini, et al.
Neurology|June 15, 2014
Prevalence of fatigue in Parkinson disease and its clinical correlatesFabrizio Stocchi, Giovanni Abbruzzese, Roberto Ceravolo, et al.
Parkinson'S Disease|December 23, 2011
The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation projectVinod Metta, Kartik Logishetty, P Martinez-Martin, et al.
Pageof 26